Explore
Validate
LearnNB100-77855
antibody from Novus Biologicals
Targeting: HLA-DRA
HLA-DRA1
Western blot
ELISA Immunocytochemistry Immunoprecipitation Immunohistochemistry Flow cytometry Blocking/Neutralizing Immunoelectron microscopy Functional assayAntibody data
- Antibody Data
- Antigen structure
- References [44]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Flow cytometry [7]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB100-77855 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB100-77855, RRID:AB_1085035
- Product name
- Mouse Monoclonal HLA-DR Antibody
- Antibody type
- Monoclonal
- Description
- Protein A purified.
- Reactivity
- Human, Canine, Simian
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 ml
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Endothelial Cell-Derived Interleukin-18 Released During Ischemia Reperfusion Injury Selectively Expands T Peripheral Helper Cells to Promote Alloantibody Production.
A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
The role of tetraspanin CD63 in antigen presentation via MHC class II.
Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies.
Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.
Extracorporeal photophoresis increases sensitivity of monocytes from patients with graft-versus-host disease to HLA-DR-mediated cell death.
Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis.
Autophagy promotes MHC class II presentation of peptides from intracellular source proteins.
Identification of HLA-DRB1-bound self-peptides following measles virus infection.
The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.
The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Humanization and characterization of the anti-HLA-DR antibody 1D10.
Humanization and characterization of the anti-HLA-DR antibody 1D10.
Determination of the HLA-DM interaction site on HLA-DR molecules.
Determination of the HLA-DM interaction site on HLA-DR molecules.
HLA-DR restricted peptide candidates for bee venom immunotherapy.
HLA-DR restricted peptide candidates for bee venom immunotherapy.
HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC.
HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC.
Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells.
Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells.
HLA-G suppresses proliferation of CD4(+) T-lymphocytes.
HLA-G suppresses proliferation of CD4(+) T-lymphocytes.
Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7.
HLA class II molecules (HLA-DR, -DP, -DQ) on cells in the human CNS studied in situ and in vitro.
The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules.
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.
Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR.
Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR.
Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression.
Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression.
Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes.
Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes.
Characterization and expression of the HLA-DC antigens defined by anti-Leu 10.
Characterization and expression of the HLA-DC antigens defined by anti-Leu 10.
Liu L, Fang C, Fu W, Jiang B, Li G, Qin L, Rosenbluth J, Gong G, Xie CB, Yoo P, Tellides G, Pober JS, Jane-Wit D
Circulation 2020 Feb 11;141(6):464-478
Circulation 2020 Feb 11;141(6):464-478
A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K, Ohira M
BMC cancer 2018 Apr 3;18(1):371
BMC cancer 2018 Apr 3;18(1):371
The role of tetraspanin CD63 in antigen presentation via MHC class II.
Petersen SH, Odintsova E, Haigh TA, Rickinson AB, Taylor GS, Berditchevski F
European journal of immunology 2011 Sep;41(9):2556-61
European journal of immunology 2011 Sep;41(9):2556-61
Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies.
Apps R, Murphy SP, Fernando R, Gardner L, Ahad T, Moffett A
Immunology 2009 May;127(1):26-39
Immunology 2009 May;127(1):26-39
Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.
Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS
The Journal of clinical investigation 2009 Aug;119(8):2143-59
The Journal of clinical investigation 2009 Aug;119(8):2143-59
Extracorporeal photophoresis increases sensitivity of monocytes from patients with graft-versus-host disease to HLA-DR-mediated cell death.
Setterblad N, Garban F, Weigl R, Assier E, Drillat P, Charron D, Dickinson A, Greinix H, Mooney N
Transfusion 2008 Jan;48(1):169-77
Transfusion 2008 Jan;48(1):169-77
Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis.
Wahlström J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanović S, Eklund A, Weissert R, Grunewald J
The Journal of clinical investigation 2007 Nov;117(11):3576-82
The Journal of clinical investigation 2007 Nov;117(11):3576-82
Autophagy promotes MHC class II presentation of peptides from intracellular source proteins.
Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, Kreymborg K, Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG, Stevanovic S
Proceedings of the National Academy of Sciences of the United States of America 2005 May 31;102(22):7922-7
Proceedings of the National Academy of Sciences of the United States of America 2005 May 31;102(22):7922-7
Identification of HLA-DRB1-bound self-peptides following measles virus infection.
Ovsyannikova IG, Johnson KL, Naylor S, Poland GA
Journal of immunological methods 2005 Feb;297(1-2):153-67
Journal of immunological methods 2005 Feb;297(1-2):153-67
The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.
Gehring AJ, Rojas RE, Canaday DH, Lakey DL, Harding CV, Boom WH
Infection and immunity 2003 Aug;71(8):4487-97
Infection and immunity 2003 Aug;71(8):4487-97
The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.
Gehring AJ, Rojas RE, Canaday DH, Lakey DL, Harding CV, Boom WH
Infection and immunity 2003 Aug;71(8):4487-97
Infection and immunity 2003 Aug;71(8):4487-97
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
Pashine A, Busch R, Belmares MP, Munning JN, Doebele RC, Buckingham M, Nolan GP, Mellins ED
Immunity 2003 Aug;19(2):183-92
Immunity 2003 Aug;19(2):183-92
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
Pashine A, Busch R, Belmares MP, Munning JN, Doebele RC, Buckingham M, Nolan GP, Mellins ED
Immunity 2003 Aug;19(2):183-92
Immunity 2003 Aug;19(2):183-92
Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, Johnson DC
Journal of virology 2002 Nov;76(21):10929-41
Journal of virology 2002 Nov;76(21):10929-41
Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, Johnson DC
Journal of virology 2002 Nov;76(21):10929-41
Journal of virology 2002 Nov;76(21):10929-41
Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS, Pashine A, Belmares MP, Liu W, Kaneshiro B, Rabinowitz J, McConnell H, Mellins ED
Journal of immunology (Baltimore, Md. : 1950) 2001 Dec 15;167(12):7157-68
Journal of immunology (Baltimore, Md. : 1950) 2001 Dec 15;167(12):7157-68
Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS, Pashine A, Belmares MP, Liu W, Kaneshiro B, Rabinowitz J, McConnell H, Mellins ED
Journal of immunology (Baltimore, Md. : 1950) 2001 Dec 15;167(12):7157-68
Journal of immunology (Baltimore, Md. : 1950) 2001 Dec 15;167(12):7157-68
Humanization and characterization of the anti-HLA-DR antibody 1D10.
Kostelny SA, Link BK, Tso JY, Vasquez M, Jorgensen BH, Wang H, Hall WC, Weiner GJ
International journal of cancer 2001 Aug 15;93(4):556-65
International journal of cancer 2001 Aug 15;93(4):556-65
Humanization and characterization of the anti-HLA-DR antibody 1D10.
Kostelny SA, Link BK, Tso JY, Vasquez M, Jorgensen BH, Wang H, Hall WC, Weiner GJ
International journal of cancer 2001 Aug 15;93(4):556-65
International journal of cancer 2001 Aug 15;93(4):556-65
Determination of the HLA-DM interaction site on HLA-DR molecules.
Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED
Immunity 2000 Oct;13(4):517-27
Immunity 2000 Oct;13(4):517-27
Determination of the HLA-DM interaction site on HLA-DR molecules.
Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED
Immunity 2000 Oct;13(4):517-27
Immunity 2000 Oct;13(4):517-27
HLA-DR restricted peptide candidates for bee venom immunotherapy.
Texier C, Pouvelle S, Busson M, Hervé M, Charron D, Ménez A, Maillère B
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 15;164(6):3177-84
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 15;164(6):3177-84
HLA-DR restricted peptide candidates for bee venom immunotherapy.
Texier C, Pouvelle S, Busson M, Hervé M, Charron D, Ménez A, Maillère B
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 15;164(6):3177-84
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 15;164(6):3177-84
HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC.
Bertho N, Drénou B, Laupeze B, Berre CL, Amiot L, Grosset JM, Fardel O, Charron D, Mooney N, Fauchet R
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 1;164(5):2379-85
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 1;164(5):2379-85
HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC.
Bertho N, Drénou B, Laupeze B, Berre CL, Amiot L, Grosset JM, Fardel O, Charron D, Mooney N, Fauchet R
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 1;164(5):2379-85
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 1;164(5):2379-85
Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells.
Appel H, Gauthier L, Pyrdol J, Wucherpfennig KW
The Journal of biological chemistry 2000 Jan 7;275(1):312-21
The Journal of biological chemistry 2000 Jan 7;275(1):312-21
Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells.
Appel H, Gauthier L, Pyrdol J, Wucherpfennig KW
The Journal of biological chemistry 2000 Jan 7;275(1):312-21
The Journal of biological chemistry 2000 Jan 7;275(1):312-21
HLA-G suppresses proliferation of CD4(+) T-lymphocytes.
Bainbridge DR, Ellis SA, Sargent IL
Journal of reproductive immunology 2000 Aug;48(1):17-26
Journal of reproductive immunology 2000 Aug;48(1):17-26
HLA-G suppresses proliferation of CD4(+) T-lymphocytes.
Bainbridge DR, Ellis SA, Sargent IL
Journal of reproductive immunology 2000 Aug;48(1):17-26
Journal of reproductive immunology 2000 Aug;48(1):17-26
Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
van Ham M, van Lith M, Lillemeier B, Tjin E, Grüneberg U, Rahman D, Pastoors L, van Meijgaarden K, Roucard C, Trowsdale J, Ottenhoff T, Pappin D, Neefjes J
The Journal of experimental medicine 2000 Apr 3;191(7):1127-36
The Journal of experimental medicine 2000 Apr 3;191(7):1127-36
Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
van Ham M, van Lith M, Lillemeier B, Tjin E, Grüneberg U, Rahman D, Pastoors L, van Meijgaarden K, Roucard C, Trowsdale J, Ottenhoff T, Pappin D, Neefjes J
The Journal of experimental medicine 2000 Apr 3;191(7):1127-36
The Journal of experimental medicine 2000 Apr 3;191(7):1127-36
CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7.
Höhn H, Pilch H, Günzel S, Neukirch C, Hilmes C, Kaufmann A, Seliger B, Maeurer MJ
Journal of immunology (Baltimore, Md. : 1950) 1999 Nov 15;163(10):5715-22
Journal of immunology (Baltimore, Md. : 1950) 1999 Nov 15;163(10):5715-22
HLA class II molecules (HLA-DR, -DP, -DQ) on cells in the human CNS studied in situ and in vitro.
Ulvestad E, Williams K, Bø L, Trapp B, Antel J, Mørk S
Immunology 1994 Aug;82(4):535-41
Immunology 1994 Aug;82(4):535-41
The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules.
Schick MR, Levy S
Journal of immunology (Baltimore, Md. : 1950) 1993 Oct 15;151(8):4090-7
Journal of immunology (Baltimore, Md. : 1950) 1993 Oct 15;151(8):4090-7
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.
Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL
The Journal of experimental medicine 1993 Jul 1;178(1):27-47
The Journal of experimental medicine 1993 Jul 1;178(1):27-47
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.
Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL
The Journal of experimental medicine 1993 Jul 1;178(1):27-47
The Journal of experimental medicine 1993 Jul 1;178(1):27-47
Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR.
Herman A, Labrecque N, Thibodeau J, Marrack P, Kappler JW, Sekaly RP
Proceedings of the National Academy of Sciences of the United States of America 1991 Nov 15;88(22):9954-8
Proceedings of the National Academy of Sciences of the United States of America 1991 Nov 15;88(22):9954-8
Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR.
Herman A, Labrecque N, Thibodeau J, Marrack P, Kappler JW, Sekaly RP
Proceedings of the National Academy of Sciences of the United States of America 1991 Nov 15;88(22):9954-8
Proceedings of the National Academy of Sciences of the United States of America 1991 Nov 15;88(22):9954-8
Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression.
Kabelitz D, Janssen O
Cellular immunology 1989 Apr 15;120(1):21-30
Cellular immunology 1989 Apr 15;120(1):21-30
Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression.
Kabelitz D, Janssen O
Cellular immunology 1989 Apr 15;120(1):21-30
Cellular immunology 1989 Apr 15;120(1):21-30
Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes.
Robbins PA, Evans EL, Ding AH, Warner NL, Brodsky FM
Human immunology 1987 Apr;18(4):301-13
Human immunology 1987 Apr;18(4):301-13
Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes.
Robbins PA, Evans EL, Ding AH, Warner NL, Brodsky FM
Human immunology 1987 Apr;18(4):301-13
Human immunology 1987 Apr;18(4):301-13
Characterization and expression of the HLA-DC antigens defined by anti-Leu 10.
Chen YX, Evans RL, Pollack MS, Lanier LL, Phillips JH, Rousso C, Warner NL, Brodsky FM
Human immunology 1984 Aug;10(4):221-35
Human immunology 1984 Aug;10(4):221-35
Characterization and expression of the HLA-DC antigens defined by anti-Leu 10.
Chen YX, Evans RL, Pollack MS, Lanier LL, Phillips JH, Rousso C, Warner NL, Brodsky FM
Human immunology 1984 Aug;10(4):221-35
Human immunology 1984 Aug;10(4):221-35
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: HLA-DR Antibody (L243) [NB100-77855] - Analysis of human spleen (A) and human tonsil (B) tissue using HLA-DR antibody at 2 ug/mL.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: HLA-DR Antibody (L243) [NB100-77855] - Staining of HLA-DR in human spleen using DAB with hematoxylin counterstain.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Human peripheral blood lymphocytes stained with L243 PE
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Alexa Fluor (R) 700 conjugate of NB100-77855. Staining of HLA-DR protein in human PBMCs using HLA-DR antibody [clone L243; conjugated to Alexa Fluor (R) 700] at 1:100 with 25 minutes incubation at 4C in 2% human serum, 0.5 mM EDTA in DPBS. Image from verified customer review.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the DyLight 405 conjugate of NB100-77855. Staining of HLA-DR in human PBMCs using anti-HLA-DR antibody. Image from verified customer review.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Biotin conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with biotinylated L243, followed by Sav-PE.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the PerCP/Cy5.5 conjugate of NB100-77855. Staining of HLA-DR expression by 5x10^5 human PBMC using 10 uL (0.25 ug) of this antibody. Cell surface flow kit was used for this test. Left panel shows the monocyte gate, right panel shows the lymphocyte gate.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow (Cell Surface): HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Azide Free version of NB100-77855. Staining of HLA-DR expression by 5x10^5 BDCM cells using 0.5 ug of (red) and 0.5 ug of isotype control (green). This antibody and an anti-mouse IgG PE conjugated secondary antibody were used.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the FITC conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with L243 FITC.
